Abstract: Biologically active molecules are inactivated for selective activation by target cells by being covalently bonded to one or more peptides each of which has one or more specific amino acid sequences that are selected in respect of enzymes cell-specific for target cells. The bonds, which are broken exclusively by the enzymes cell-specific for the target cells in order to biologically activate the molecules, allow the molecules to remain biologically inactive in cells other than the target cells. The molecules are used for influencing gene expression of preferably sick and infected organs or cells, for example.
Abstract: The invention relates to a method for cleaving cervimycin esters. An object of the invention to convert in a simple manner the cervimycin esters which are less active but formed in larger quantity into the highly active cervimycin K that occurs as a minor component in the preparation by fermentation, is achieved by preparing unesterified cervimycins from cervimycin esters with di- or monomethylated malonic acids, by ester cleavage effected by at least one esterolytic enzyme at temperatures of 20° C. to 75° C. and a pH of pH 5.0 to 10.0, preferably pH 6.0 to 9.0.
September 25, 2006
June 4, 2009
LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFE, FRIEDRICH-SCHILLER-UNIVERSITÄT JENA
Abstract: A method and apparatus for determining fluorophores on objects, especially on the living ocular fundus, which makes it possible to reliably distinguish at least partially overlapping fluorophores of objects in excitation and/or fluorescence spectra even if fluorescence intensities are very low and to select them for analysis, and optionally create a two-dimensional representation. The object (4), e.g., the ocular fundus for ophthalmological examinations, is illuminated point to point with a pulsed laser (1) and excited to autofluorescence with two-dimensional extension. The transient fluorescence light created after excitation by each laser pulse is detected in time-correlated individual photon counting (11). From the time behavior of the fluorescence light determined by individual photon counting for each site of autofluorescence, the fluorescence decay time constants are calculated, and conclusions are drawn therefrom regarding the excited fluorophores in the object (4).
May 1, 2000
Date of Patent:
April 16, 2002
Friedrich-Schiller-Universität Jena Buero für
Dietrich Schweitzer, Achim Kolb, Martin Hammer, Eike Thamm
Abstract: The invention relates to inorganic-organic compound substances useful for biomedical purposes. The object of the invention is to develop inorganic-organic compound materials which overcome the disadvantages of the state of art, wherein inorganic-organic compound substances for biomedical purposes possess to a large extent specifically adjustable characteristics. Inorganic initial substances form a new solid chemical compound with organic initial substances. The inorganic initial component consists of a biocompatible silicate glass and/or a silicate glass ceramic of the system SiO.sub.2 -Al.sub.2 O.sub.3 -MgO-Na.sub.2 O/K.sub.2 O-F.sup.-, and/or a bioactive phosphate silicate glass and/or a phosphate silicate glass ceramic of the system SiO.sub.2 -Al.sub.2 O.sub.3 -MgO-Na.sub.2 O/K.sub.2 O-CaO-P.sub.2 O.sub.5 F.sup.- and/or of the system SiO.sub.2 -MgO-K.sub.2 O-F.sup.- -CaO-P.sub.2 O.sub.5, and/or a bioactive phosphate glass and/or a phosphate glass ceramic of the system P.sub.2 O.sub.5 -Al.sub.2 O.sub.
June 12, 1986
Date of Patent:
March 15, 1988
Werner Vogel, Guenther Heublein, Wolfram Hoeland, Manfred Boese, Karin Naumann, Gunter Carl, Juergen Vogel, Peter Wange, Jens Gummel, Peter Zinner, Eggert Beleites, Thomas Schubert